葵花药业
(002737)
| 流通市值：159.02亿 | | | 总市值：159.02亿 |
| 流通股本：5.84亿 | | | 总股本：5.84亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,235,195,578.94 | 3,033,922,653.76 | 1,765,521,894.46 | 5,094,511,319.93 |
| 营业收入 | 4,235,195,578.94 | 3,033,922,653.76 | 1,765,521,894.46 | 5,094,511,319.93 |
| 二、营业总成本 | 3,258,920,901.62 | 2,268,068,166.55 | 1,263,633,787.02 | 4,055,839,953.55 |
| 营业成本 | 1,768,053,148.97 | 1,239,815,365.67 | 714,027,194.57 | 2,152,457,415.29 |
| 税金及附加 | 47,904,431.43 | 34,234,213.82 | 18,310,234.27 | 69,404,207.52 |
| 销售费用 | 1,008,968,440.65 | 719,950,300.24 | 398,128,323.57 | 1,274,273,752.65 |
| 管理费用 | 363,817,102.89 | 243,596,584.08 | 117,564,972.41 | 476,246,679.97 |
| 研发费用 | 95,100,931.2 | 47,228,443.45 | 21,168,133.51 | 94,614,417.97 |
| 财务费用 | -24,923,153.52 | -16,756,740.71 | -5,565,071.31 | -11,156,519.85 |
| 其中:利息费用 | 4,458,583.36 | 4,027,884.25 | 3,211,753.12 | 9,726,164.81 |
| 其中:利息收入 | 29,063,329.78 | 20,995,146.49 | 8,891,322.77 | 21,171,336.35 |
| 加:公允价值变动收益 | -14,216,093.77 | -15,372,824.07 | -2,297,992.58 | -19,307,451.09 |
| 加:投资收益 | 25,468,607.54 | 24,698,446.29 | 2,726,237.48 | 9,389,717.16 |
| 资产处置收益 | 1,031,951.93 | 907,650.19 | 626,037.13 | 7,430,840.95 |
| 资产减值损失(新) | 161,645.56 | 667,842.85 | -2,675,330.18 | -29,357,929.45 |
| 信用减值损失(新) | 1,410,917.07 | -3,716,322.31 | -1,638,001.65 | -5,220,152.78 |
| 其他收益 | 53,547,326.09 | 44,084,470.89 | 16,282,041.89 | 83,383,686.81 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,043,679,031.74 | 817,123,751.05 | 514,911,099.53 | 1,084,990,077.98 |
| 加:营业外收入 | 1,334,402.14 | 959,156.95 | 121,512.11 | 2,777,841.3 |
| 减:营业外支出 | 8,718,120.65 | 2,242,917.92 | 251,949.14 | 6,662,604.62 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,036,295,313.23 | 815,839,990.08 | 514,780,662.5 | 1,081,105,314.66 |
| 减:所得税费用 | 149,238,817.96 | 136,933,869.42 | 79,415,781.39 | 171,406,218.54 |
| 六、净利润 | 887,056,495.27 | 678,906,120.66 | 435,364,881.11 | 909,699,096.12 |
| 持续经营净利润 | 887,056,495.27 | 678,906,120.66 | 435,364,881.11 | 909,699,096.12 |
| 归属于母公司股东的净利润 | 851,186,073.7 | 638,159,703.16 | 406,135,072.45 | 867,186,130.47 |
| 少数股东损益 | 35,870,421.57 | 40,746,417.5 | 29,229,808.66 | 42,512,965.65 |
| (一)基本每股收益 | 1.47 | 1.1 | 0.7 | 1.48 |
| (二)稀释每股收益 | 1.46 | 1.09 | 0.7 | 1.48 |
| 八、其他综合收益 | 13,104 | 209,292.63 | -2,312.75 | -133,660.8 |
| 归属于母公司股东的其他综合收益 | 9,172.8 | 222,265.59 | -3,098.99 | -93,562.56 |
| 九、综合收益总额 | 887,069,599.27 | 679,115,413.29 | 435,362,568.36 | 909,565,435.32 |
| 归属于母公司股东的综合收益总额 | 851,195,246.5 | 638,381,968.75 | 406,131,973.46 | 867,092,567.91 |
| 归属于少数股东的综合收益总额 | 35,874,352.77 | 40,733,444.54 | 29,230,594.9 | 42,472,867.41 |
| 公告日期 | 2023-10-26 | 2023-08-25 | 2023-04-28 | 2023-04-12 |
| 审计意见(境内) | | | | 标准无保留意见 |